Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Monitoring Agency Report for the quarter ended September 30, 2023.10-11-2023
10-11-2023
Q2FY24 Quarterly & H1FY24 Bi-Annual Result Announced for Global Health Ltd.
Healthcare Facilities company Global Health announced Q2FY24 & H1FY24 results: Q2FY24: Total income of Rs 8,647 million; growth of 24.5% YoY EBITDA of Rs 2,336 million; growth of 35.7% YoY EBITDA margins improved from 24.8% in Q2FY23 to 27% in Q2FY24 Profit after tax was at Rs 1,252 million; up by 46.1% YoY Average Occupied bed days increased by 17.8% YoY, representing an occupancy of 64.9% in Q2FY24 ARPOB grew by 4.8% YoY to Rs 61,003; In-patient count increased by 19.4% and Out-patient count increased by 23.2% YoY Developing hospitals (Medanta Lucknow and Medanta Patna) revenue share increased from 27% in Q2FY23 to 31% in Q2FY24 amounting to Rs 2,643 million. Developing Hospital EBITDA share increased from 33% in Q2FY23 to 38% in Q2FY24 amounting to Rs 897 million Matured hospitals registered a strong growth of 19.5% YoY and EBITDA growth of 32.8% YoY amounting to Rs 6,064 million and Rs 1,545 million respectively Revenue from international patients increased by 20% YoY to Rs 507 million driven by increased volumes and realization OPD pharmacy business continues to register strong growth. Revenue increased by 39% YoY from Rs 215 million in Q2FY23 to Rs 298 million in Q2FY24 H1FY24: Total income of Rs 16,592 million; growth of 25.6% YoY EBITDA of Rs 4,329 million; growth of 38.0% YoY EBITDA margins improved from 23.7 % in H1FY23 to 26.1% in H1FY24 Profit after tax of Rs 2,272 million; growth of 57.3% YoY Average Occupied bed days increased by 17.1% YoY, representing an occupancy of 61.5% in H1FY24 ARPOB grew by 5.9% YoY to Rs 62,011 in H1FY24; In-patient volume increased by 19.4% and Out-patient volume increased by 20.5% YoY in H1FY24 incurred Capex of Rs 1,276 million incurred during H1FY24, out of which Rs 308 million was incurred towards Noida hospital Commenting on Q2FY24 results, Pankaj Sahni, Group CEO and Director said, “We are pleased to report that the Company continues to deliver strong year-on-year and sequential growth across key performance indicators. The growth was seen at both matured and developing units, driven by higher patient volumes, underpinned by bed growth, doctor additions, and technology advancement. During the quarter, we received NABH accreditation for Patna Hospital, this accreditation reflects our commitment to deliver the highest quality healthcare in underserved markets. Our Noida hospital construction is on track and is expected to commence operations by FY2025 the end. As we move forward, we remain committed to executing our planned strategies while maintaining the highest quality and ethics as demonstrated by our ‘Medanta Model of Care’. Result PDF09-11-2023
Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for Quarter and Half Year Ended September 30, 2023 Results of the Company.09-11-2023
Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release for Second Quarter and Half year ended Sep 30, 202309-11-2023
Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting dated 15 November, 2023.09-11-2023
Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Acquisition
Special Purpose Company to be incorporated jointly by DLF Limited and GHL, in which both companies will have 50.50 Equity Shareholding.09-11-2023
Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Joint Venture
The Board of Directors of the Company at its meeting held today i.e. November 9, 2023 has approved execution of definitive agreements along with other necessary papers for jointly incorporation of Special Purpose vehicle with M/s DLF Limited.09-11-2023
Global Health Ltd - 543654 - Statement Of Deviation/Variation In Utilization Of Funds Raised Through Initial Public Offer ('IPO') For The Quarter Ended September 30, 2023
Statement of Deviation/variation in utilization of funds raised through IPO for the Quarter Ended September 30, 2023.09-11-2023
Global Health Ltd - 543654 - Board Meeting Outcome for Outcome Of Board Meeting Dated November 9, 2023
We would like to inform you that the Board of Directors of Global Health Limited ('GHL/Company') at its meeting held today i.e. Thursday, November 9, 2023, inter-alia, has approved the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and Half year ended September 30, 2023 ('Results'). The certified copies of Results along with Limited Review Reports from the Statutory Auditors M/s Walker Chandiok & Co LLP, Chartered Accountants thereon, are enclosed herewith as Exhibit, Further, in continuance with our earlier intimation dated August 10, 2023, Re. development of a 400 bed multi-specialty hospital in Delhi along with M/s DLF Limited, please note that, the Board of Directors of the Company at its meeting held today has approved execution of definitive agreement for jointly incorporation of Special Purpose Vehicle (SPV) with M/s DLF Limited. The details is attached.09-11-2023
Global Health Ltd - 543654 - RESULTS-QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2023
We would like to inform you that the Board has approved Unaudited standalone and consolidated Financial Results for the Quarter and half year ended September 30, 2023.09-11-2023